HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N'- ((6- bromoimidazo(1,2- a)pyridin- 3- yl)methylene)- N- ethyl- 2- methyl- 5- nitrobenzohydrazide

structure in first source

Also Known As:

DW09849

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - N'-((6-bromoimidazo(1,2-a)pyridin-3-yl)methylene)-N-ethyl-2-methyl-5-nitrobenzohydrazide: 1
Organic Chemicals: 133
- Hydrazines: 379
  - Hydrazones: 500
    - N'-((6-bromoimidazo(1,2-a)pyridin-3-yl)methylene)-N-ethyl-2-methyl-5-nitrobenzohydrazide: 1

Experts

1.	Cao, Su-fen: 1 article (03/2014)
2.	Ding, Jian: 1 article (03/2014)
3.	Duan, Wen-hu: 1 article (03/2014)
4.	Gao, Guo-rui: 1 article (03/2014)
5.	Guo, Chen-liang: 1 article (03/2014)
6.	Liu, Jia-li: 1 article (03/2014)
7.	Meng, Ling-hua: 1 article (03/2014)
8.	Tong, Lin-jiang: 1 article (03/2014)
9.	Wang, Xiang: 1 article (03/2014)
10.	Zhang, Xi: 1 article (03/2014)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2014 - "These results suggest that DW series compounds, especially DW09849, selectively targeting PI3Kα with less off-target effects than PIK-75, provide new clues for the design and discovery of new specific PI3Kα inhibitors for cancer therapy. "
2.	Breast Neoplasms (Breast Cancer) 03/01/2014 - "Moreover, DW09849 selectively suppressed the proliferation and clonogenesis of transformed RK3E/HR cells harboring oncogenic mutation of p110α H1047R, as well as a panel of human breast cancer cells containing mutated PI3Kα, which is consistent with the finding that DW09849 demonstrated preference against H1047R mutated PI3Kα in molecular docking stimulation. "

Related Drugs and Biologics

1.	PIK 75

Related Therapies and Procedures

1.	Therapeutics